SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Xenetic Biosciences, Inc. (XBIOW) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — XBIOW
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio10.03
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.58
Book Value / Share$0.00
Revenue / Share$1.75
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-875.41 |
$3M |
$-54.21M |
-1806.9% |
| 2017 |
$-49.78 |
$7.59M |
$-3.6M |
-47.4% |
| 2018 |
$-96.57 |
$0.00 |
$-7.3M |
- |
| 2019 |
$-55.92 |
$17.07K |
$-15.95M |
-93460.2% |
| 2020 |
$-17.04 |
$436.94K |
$-10.89M |
-2493.1% |
| 2021 |
$-5.39 |
$1.16M |
$-5.54M |
-477.7% |
| 2022 |
$-4.49 |
$1.71M |
$-6.39M |
-374.2% |
| 2023 |
$-2.71 |
$2.54M |
$-4.13M |
-162.8% |
| 2024 |
$-2.57 |
$2.5M |
$-3.96M |
-158.4% |
| 2025 |
$-1.58 |
$2.98M |
$-2.68M |
-90.1% |
